Chromocell Therapeutics Overview
Chromocell Therapeutics (CHRO) has a P/E ratio of -0.05, below the sector sector average of 47.3.
Get informed when a big investor buys or sells
+ Follow-0.05
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Chromocell Therapeutics (CHRO) currently reports a P/E ratio of -0.05. That is below the sector sector average of 47.3. Use the charts on this page to explore Chromocell Therapeutics's P/E ratio history and peer comparisons.
Chromocell Therapeutics's P/E ratio of -0.05 is lower than the its sector sector average of 47.3. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Chromocell Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.05, CHRO can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.05, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 47.3. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.
